VASCULAR SMOOTH MUSCLE REMODELING IN RESPONSE TO ARGININE VASOPRESSIN
VASCULAR SMOOTH MUSCLE REMODELING IN RESPONSE TO ARGININE VASOPRESSIN
批准号:
7467363
负责人:
RAPHAEL A. NEMENOFF
金额:
$38.55万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-08-01 至 2009-07-31
关键词:
1-Phosphatidylinositol 3-KinaseAdultAffinityArginineArgipressinBindingBlood VesselsCardiacCell-Matrix JunctionCellsCharacteristicsCytoskeletonDevelopmentDiseaseElementsEmbryoEventExtracellular MatrixFamilyFamily memberFocal Adhesion Kinase 1Focal AdhesionsFundingGene ExpressionGene TargetingGenesGenetic TranscriptionGenomicsGoalsGrowthGrowth FactorIndividualIntegrinsLeadMAPK14 geneMAPK8 geneMapsMechanicsMediatingMediator of activation proteinMitogen-Activated Protein KinasesMolecularMonomeric GTP-Binding ProteinsMuscleNeonatalNuclearNumbersPathway interactionsPatternPhenotypePhosphoinositide-3-Kinase, Catalytic, Gamma PolypeptidePhosphorylationPhosphorylation SitePlatelet-Derived Growth FactorProcessProtein IsoformsProtein KinaseProteinsRangeRegulationResearch PersonnelRoleSerum Response FactorSignal TransductionSignal Transduction PathwaySkeletal MuscleSmooth MuscleSmooth Muscle MyocytesStimulusTestingTranscriptional RegulationVascular Smooth MuscleVascular remodelingVasoconstrictor Agentsbaseextracellularin vivo Modelmembermutantplatelet-derived growth factor BBprogramspromoterresponserhotranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
During normal development, vascular smooth muscle cells (VSMC) undergo differentiation from a
proliferative phenotype characteristic of neonatal and embryonic vessels, to a contractile phenotype associated with adult vessels. In contrast to development of cardiac or skeletal muscle, VSMC retain much greater plasticity. In adult VSMC, phenotypic modulation resulting in changes in altered expression of a number of muscle-specific genes (SM-markers), results in cells with altered contractile, proliferative and migratory capacity. Transcriptional control of these genes occurs in response to multiple extracellular stimuli including circulating factors, extracellular matrix and mechanical forces. We hypothesize that phenotypic modulation requires sensing by VSMC of these multiple inputs, which integrate at the level of common signal transduction pathways. These pathways act on transcription factors, most critically serum
response factor (SRF), that bind to the promoter elements of multple target genes. The goal of this proposal is to define these molecular signaling events and determine how they regulate transcription. During the previous funding period we have demonstrated that coordinated induction of SM-markers by arginine vasopression (AVP) is mediated through activation of the JNK and p38 family of MAP kinases. Induction by mechanical forces also involves these pathways. Conversely, PDGF suppression of SM-gene expression is mediated through activation of Ras and the PI3 kinase/Akt pathways. We have also demonstrated that growth
of VSMC on matrices of different composition, through engagement of specific integrins and modulation of cytoskeleton, results in changes in expression of SM-markers. SRF is critical for regulation in all of these settings, and shows altered phosphorylation and subcellular localization. In this application we will focus on understanding the integration of signals generated by vasoconstrictors such as AVP, growth factors, and cell attachment resulting in alterations in gene expression. Three specific aims are proposed. Specific aim 1 will
examine the role of MAP kinase and Rho family members in mediating the inductive effects of AVP. The second specific aim will define the mechanisms whereby Ras and Akt cooperate to mediate regulation of SM-gene expression by PDGF and redistribution of SRF. The final specific aim will examine the role of SRF phosphorylation in mediating control of SM-gene expression. These studies should provide a detailed molecular understanding of the events that control phenotypic remodeling in VSMC, and provide potential new targets for controlling this process in disease states.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Colorado HNC SPORE Career Enhancement Program
-
批准号:10704608
-
项目类别:
-
资助金额:$9.11万
-
财政年份:2021
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Colorado HNC SPORE Career Enhancement Program
-
批准号:10477471
-
项目类别:
-
资助金额:$9.11万
-
财政年份:2021
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
The Lung Tumor Microenvironment: Role of Resident Pulmonary Vascular Progenitor Cells in Cancer Progression and Metastasis
-
批准号:10097362
-
项目类别:
-
资助金额:$21.81万
-
财政年份:2020
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
The Lung Tumor Microenvironment: Role of Resident Pulmonary Vascular Progenitor Cells in Cancer Progression and Metastasis
-
批准号:10308484
-
项目类别:
-
资助金额:$17.81万
-
财政年份:2020
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Effects of Complement on the Tumor Microenvironment in Lung Cancer
-
批准号:10303019
-
项目类别:
-
资助金额:$39.49万
-
财政年份:2018
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Effects of Complement on the Tumor Microenvironment in Lung Cancer
-
批准号:10521237
-
项目类别:
-
资助金额:$39.49万
-
财政年份:2018
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Effects of Complement on the Tumor Microenvironment in Lung Cancer
-
批准号:10053335
-
项目类别:
-
资助金额:$40.29万
-
财政年份:2018
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Eicosanoids in Lung Cancer: Progression and Metastasis
-
批准号:8786871
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2013
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Eicosanoids in Lung Cancer: Progression and Metastasis
-
批准号:8446051
-
项目类别:
-
资助金额:$31.96万
-
财政年份:2013
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Eicosanoids in Lung Cancer: Progression and Metastasis
-
批准号:9197948
-
项目类别:
-
资助金额:$32.27万
-
财政年份:2013
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Eicosanoids in Lung Cancer: Progression and Metastasis
-
批准号:8598081
-
项目类别:
-
资助金额:$31.1万
-
财政年份:2013
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Eicosanoids in Lung Cancer: Progression and Metastasis
-
批准号:8985661
-
项目类别:
-
资助金额:$32.27万
-
财政年份:2013
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Prostacyclin and Peroxisome Proliferator- Activated Receptor Gamma in Lung Cancer
-
批准号:7448824
-
项目类别:
-
资助金额:$19.36万
-
财政年份:2008
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Preroxisome Proliferator-Activated Receptors in lung Cancer
-
批准号:7091460
-
项目类别:
-
资助金额:$29.75万
-
财政年份:2004
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Peroxisome Proliferator Activated Receptors in Cancer
-
批准号:6807840
-
项目类别:
-
资助金额:$30.46万
-
财政年份:2004
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Peroxisome Proliferator-Activated Receptor (gamma) in Lung Cancer
-
批准号:8786993
-
项目类别:
-
资助金额:$29.74万
-
财政年份:2004
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Preroxisome Proliferator-Activated Receptors in lung Cancer
-
批准号:6932277
-
项目类别:
-
资助金额:$30.46万
-
财政年份:2004
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
VASCULAR SMOOTH MUSCLE REMODELING--ARGININE VASOPRESSIN
-
批准号:6851011
-
项目类别:
-
资助金额:$36.45万
-
财政年份:2004
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Peroxisome Proliferator Activated Receptors in Lung Cancer
-
批准号:7409657
-
项目类别:
-
资助金额:$28.88万
-
财政年份:2004
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
Peroxisome Proliferator Activated Receptors in Lung Cancer
-
批准号:7231475
-
项目类别:
-
资助金额:$28.88万
-
财政年份:2004
-
负责人:RAPHAEL A. NEMENOFF
-
依托单位:
海外基金